Article info

Original research
Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections

Authors

  • Rani Burm Laboratory of Liver Infectious Diseases (LLID), Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium PubMed articlesGoogle scholar articles
  • Panagiota Maravelia Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden PubMed articlesGoogle scholar articles
  • Gustaf Ahlen Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden PubMed articlesGoogle scholar articles
  • Sandra Ciesek Institute for Medical Virology, University Hospital, Goethe University, Frankfurt am Main, GermanyFraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, GermanyGerman Center for Infection Research, DZIF, External partner site, Frankfurt am Main, Germany PubMed articlesGoogle scholar articles
  • Noelia Caro Perez Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden PubMed articlesGoogle scholar articles
  • Anna Pasetto Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden PubMed articlesGoogle scholar articles
  • Stephan Urban Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, Germany PubMed articlesGoogle scholar articles
  • Freya Van Houtte Laboratory of Liver Infectious Diseases (LLID), Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium PubMed articlesGoogle scholar articles
  • Lieven Verhoye Laboratory of Liver Infectious Diseases (LLID), Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium PubMed articlesGoogle scholar articles
  • Heiner Wedemeyer Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany PubMed articlesGoogle scholar articles
  • Magnus Johansson School of Medical Sciences, Inflammatory Response and Infection Susceptibility Centre (iRiSC), Faculty of Medicine and Health, Örebro University, Orebro, Sweden PubMed articlesGoogle scholar articles
  • Lars Frelin Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden PubMed articlesGoogle scholar articles
  • Matti Sällberg Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden PubMed articlesGoogle scholar articles
  • Philip Meuleman Laboratory of Liver Infectious Diseases (LLID), Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Philip Meuleman, Laboratory of Liver Infectious Diseases (LLID), Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University, Gent, Belgium; philip.meuleman{at}ugent.be; Professor Matti Sällberg, Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; matti.sallberg{at}ki.se
View Full Text

Citation

Burm R, Maravelia P, Ahlen G, et al
Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections

Publication history

  • Received February 18, 2022
  • Accepted July 29, 2022
  • First published August 17, 2022.

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.